- Okamoto, Shu-ichi;
- Nakamura, Tomohiro;
- Cieplak, Piotr;
- Chan, Shing Fai;
- Kalashnikova, Evgenia;
- Liao, Lujian;
- Saleem, Sofiyan;
- Han, Xuemei;
- Clemente, Arjay;
- Nutter, Anthony;
- Sances, Sam;
- Brechtel, Christopher;
- Haus, Daniel;
- Haun, Florian;
- Sanz-Blasco, Sara;
- Huang, Xiayu;
- Li, Hao;
- Zaremba, Jeffrey D;
- Cui, Jiankun;
- Gu, Zezong;
- Nikzad, Rana;
- Harrop, Anne;
- McKercher, Scott R;
- Godzik, Adam;
- Yates, John R;
- Lipton, Stuart A
Redox-mediated posttranslational modifications represent a molecular switch that controls major mechanisms of cell function. Nitric oxide (NO) can mediate redox reactions via S-nitrosylation, representing transfer of an NO group to a critical protein thiol. NO is known to modulate neurogenesis and neuronal survival in various brain regions in disparate neurodegenerative conditions. However, a unifying molecular mechanism linking these phenomena remains unknown. Here, we report that S-nitrosylation of myocyte enhancer factor 2 (MEF2) transcription factors acts as a redox switch to inhibit both neurogenesis and neuronal survival. Structure-based analysis reveals that MEF2 dimerization creates a pocket, facilitating S-nitrosylation at an evolutionally conserved cysteine residue in the DNA binding domain. S-Nitrosylation disrupts MEF2-DNA binding and transcriptional activity, leading to impaired neurogenesis and survival in vitro and in vivo. Our data define a molecular switch whereby redox-mediated posttranslational modification controls both neurogenesis and neurodegeneration via a single transcriptional signaling cascade.